ImmuCell Corporation entered into a new settlement agreement with Norbrook Laboratories on May 8, 2026. The companies signed a Settlement Deed that resolves and releases all claims related to their 2019 Development Services and Commercial Supply Agreement, which expired March 31, 2026. Under this Settlement Deed, Norbrook will pay ImmuCell $2,000,000, providing a one-time cash benefit to ImmuCell. The agreement is governed by Northern Ireland law, contains confidentiality undertakings, and explicitly states it is not an admission of liability or wrongdoing by either party.
ImmuCell Corporation is asking stockholders to vote at its June 11, 2026 virtual annual meeting. Holders of 9,046,799 common shares as of April 13, 2026 can elect seven directors, cast an advisory “say-on-pay” vote, and ratify Wipfli LLP as auditor.
Stockholders are also asked to approve the 2025 Stock Option and Incentive Plan, which authorizes up to 650,000 shares and has 403,777 options already granted, largely contingent on approval, and to amend the charter to add Delaware-permitted officer exculpation.
The proxy highlights a leadership transition to new CEO P. Olivier te Boekhorst, a strategic focus on the First Defense® product line, efforts to partner Re-Tain®, creation of a Strategy & Technology Committee, and updated compensation and equity policies for executives and directors.
ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options. These options cover 17,899 shares of common stock at an exercise price of $7.60 per share and expire on April 15, 2036.
The options vest over three years: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares on April 15, 2029. This filing records DiMarco’s derivative equity position; it does not show any recent buy or sell transaction.
ImmuCell Corp (ICCC) director Gilles Guillemette filed an initial Form 3 reporting stock option holdings. The filing shows non-qualified stock options to acquire 17,899 shares of common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest in three equal annual installments: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares become exercisable on April 15, 2029. All reported holdings are owned directly.
ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options give her the right to buy an equal number of ImmuCell common shares at an exercise price of $7.60 per share and represent a compensation award rather than an open-market purchase.
The options vest over three years, with 5,966 options becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 options vesting on April 15, 2029. All of the options expire on April 15, 2036 if they are not exercised.
ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.
ImmuCell director Gloria F. Basse received a grant of 11,933 non-qualified stock options to buy ImmuCell common stock. The options have an exercise price of $7.60 per share and expire on April 15, 2036.
All 11,933 options were awarded as compensation and are held directly. According to the vesting schedule, 3,977 options become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 options become exercisable on April 15, 2029.
ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation. He was awarded options to buy 11,933 shares of ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over three years: 3,977 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares on April 15, 2029. After this grant, Wainman holds 11,933 stock options directly, indicating a compensation-related equity award rather than an open-market purchase or sale.
ImmuCell Corporation is soliciting proxies for its remote Annual Meeting of Stockholders to be held June 11, 2026, with a record date of April 13, 2026. The meeting will consider: election of seven directors; a non-binding advisory vote on executive compensation; approval of the 2025 Stock Option and Incentive Plan; an amendment to the Certificate of Incorporation to add officer exculpation under Delaware law; and ratification of Wipfli LLP as independent auditors.
The 2025 Plan would authorize up to 650,000 shares. The proxy discloses director pay changes (non-employee director annual fee increased to $40,000 effective January 1, 2026), named executive officer compensation details (e.g., CEO total 2025 compensation $675,934), outstanding option and plan balances (total options outstanding 801,760; weighted-average exercise price $6.20), and governance items including committee structures and related-party disclosure.
ImmuCell Corp. director Bryan K. Gathagan received a grant of non-qualified stock options for 10,000 shares of common stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this grant, he holds 10,000 options directly.